BIOMAT Database Logo BIOMAT Database Logo

GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. 2023

Bijan Boldajipour, and Gary Lee, and Tina Albertson
Lyell Immunopharma, South San Francisco, CA glee@lyell.com.

UI MeSH Term Description Entries

Related Publications

Bijan Boldajipour, and Gary Lee, and Tina Albertson
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.
April 2023, The New England journal of medicine,
Bijan Boldajipour, and Gary Lee, and Tina Albertson
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. Reply.
June 2023, The New England journal of medicine,
Bijan Boldajipour, and Gary Lee, and Tina Albertson
Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma.
February 2015, Pediatric hematology and oncology,
Bijan Boldajipour, and Gary Lee, and Tina Albertson
Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma.
March 2021, Cancers,
Bijan Boldajipour, and Gary Lee, and Tina Albertson
Intraoperative Radiation Therapy for Relapsed or Refractory High-Risk Neuroblastoma: A 27-Year Experience.
January 2024, Practical radiation oncology,
Bijan Boldajipour, and Gary Lee, and Tina Albertson
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis.
November 2020, Nature medicine,
Bijan Boldajipour, and Gary Lee, and Tina Albertson
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results.
June 2023, Nature medicine,
Bijan Boldajipour, and Gary Lee, and Tina Albertson
Irinotecan plus temozolomide for relapsed or refractory neuroblastoma.
November 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Bijan Boldajipour, and Gary Lee, and Tina Albertson
Author Correction: Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results.
January 2024, Nature medicine,
Bijan Boldajipour, and Gary Lee, and Tina Albertson
Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma.
February 2022, Biomolecules,
Copied contents to your clipboard!